Insider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Acquires 83,334 Shares of Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels acquired 83,334 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average cost of $0.12 per share, for a total transaction of $10,000.08. Following the purchase, the chief executive officer now owns 1,764,029 shares of the company’s stock, valued at approximately $211,683.48. The trade was a 4.96 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

AIM ImmunoTech Stock Up 0.7 %

AIM stock opened at $0.12 on Wednesday. The company has a 50 day moving average price of $0.18 and a two-hundred day moving average price of $0.23. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market capitalization of $8.32 million, a P/E ratio of -0.26 and a beta of 0.41. AIM ImmunoTech Inc. has a one year low of $0.11 and a one year high of $0.62.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their target price on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Tuesday, December 10th.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).